Couple of reasons
"Led to a circa 65% reduction in tumour size in mice treated with the combination
therapy" Combo therapy, not enough detail in announcement to say if INV043 showed any real benefit over the approved PD-1 being used.
"Tumours were also significantly smaller than those in mice that received monotherapy"
Ok, great. Where's the detail? What dose were the treatment arm given?
Devil is in the detail, and there's not enough here.
Ann: INV043 SIGNIFICANTLY IMPROVED CHECKPOINT INHIBITOR THERAPY, page-15
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.91M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $9.046K | 3.013M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 551376 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 11132211 | 12 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IVX (ASX) Chart |